LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.

Yi‐Long Wu, Sarayut Lucien Geater, Chengping Hu et al.|Journal of Clinical Oncology|2013

Cited by 83